scholarly journals A comparison of fluconazole oral suspension and amphotericin B oral suspension in older patients with oropharyngeal candidosis

2000 ◽  
Vol 29 (2) ◽  
pp. 117-123 ◽  
Author(s):  
J Taillander
Keyword(s):  
Amphotericin B ◽  
Older Patients ◽  
Oral Suspension

Stability of amphotericin B in an extemporaneously compounded oral suspension

2001 ◽  
Vol 58 (11) ◽  
pp. 1021-1024 ◽  
Author(s):  
Paul J. Dentinger ◽  
Chad F. Swenson ◽  
Nasr H. Anaizi
Keyword(s):  
Amphotericin B ◽  
Oral Suspension

Assessment of Antifungal Therapy in an 800-Gram Infant with Candidal Arthritis and Osteomyelitis

PEDIATRICS ◽  
1983 ◽  
Vol 72 (2) ◽  
pp. 234-238 ◽  
Author(s):  
Robert M. Ward ◽  
Fred R. Sattler ◽  
A. Stanley Dalton
Keyword(s):  
Amphotericin B ◽  
Antifungal Therapy ◽  
Older Patients ◽  
Bone Erosion ◽  
Serum Levels ◽  
Joint Fluid ◽  
Bone Marrow Toxicity ◽  
Drug Induced ◽  
Transient Elevation ◽  
Systemic Antibiotics

A 720-g premature newborn developed disseminated candidiasis during treatment with systemic antibiotics and total parenteral nutrition through an umbilical arterial catheter. Clinical features were typical for candidal skeletal infection at this age and included warmth and fusiform swelling of the lower extremities together with radiographic evidence of osteolysis and cortical bone erosion. Candida albicans was cultured from blood, urine, joint fluid, and a bone aspirate. The infection was cured with a 44-day course of amphotericin B and flucytosine (5-fluorocytosine). Antifungal therapy was monitored closely with serum drug levels and laboratory tests for bone marrow toxicity and renal dysfunction. Serum levels of both drugs were comparable to those achieved in older patients treated with similar doses. Significant concentrations of amphotericin B were detected in serum four and 17 days after completion of therapy, indicating a slow rate of elimination similar to that which occurs in adults. There was no evidence of drug-induced toxicity other than transient elevation in the fractional urinary excretion of sodium. This suggests that antifungal therapy may be effectively and safely administered to infants in dose schedules similar to those used for older patients.

scholarly journals Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)

2019 ◽  
Vol 74 (11) ◽  
pp. 3315-3327 ◽  
Author(s):  
Jon Salmanton-García ◽  
Danila Seidel ◽  
Philipp Koehler ◽  
Sibylle C Mellinghoff ◽  
Raoul Herbrecht ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Standard Treatment ◽  
Treatment Options ◽  
Oral Suspension ◽  
First Line ◽  
Limited Sample ◽  
All Cause Mortality ◽  
Cautious Interpretation ◽  
Paired Analysis ◽  
Matched Paired Analysis

Abstract Background First-line antifungal treatment for invasive mucormycosis (IM) consists of liposomal amphotericin B. Salvage treatment options are limited and often based on posaconazole oral suspension. With the approval of posaconazole new formulations, patients could benefit from improved pharmacokinetics, safety and tolerability. Objectives Our aim was to assess the effectiveness of posaconazole new formulations for IM treatment. Methods We performed a case-matched analysis with proven or probable IM patients from the FungiScope® Registry. First-line posaconazole new formulations (1st-POSnew) and first-line amphotericin B plus posaconazole new formulations (1st-AMB+POSnew) cases were matched with first-line amphotericin B-based (1st-AMB) treatment controls. Salvage posaconazole new formulations (SAL-POSnew) cases were matched with salvage posaconazole oral suspension (SAL-POSsusp) controls. Each case was matched with up to three controls (based on severity, haematological/oncological malignancy, surgery and/or renal dysfunction). Results Five patients receiving 1st-POSnew, 18 receiving 1st-AMB+POSnew and 22 receiving SAL-POSnew were identified. By day 42, a favourable response was reported for 80.0% (n = 4/5) of patients receiving 1st-POSnew, for 27.8% (n = 5/18) receiving 1st-AMB+POSnew and for 50.0% (n = 11/22) receiving SAL-POSnew. Day 42 all-cause mortality of patients receiving posaconazole new formulations was lower compared with controls [20.0% (n = 1/5) in 1st-POSnew versus 53.3% (n = 8/15) in 1st-AMB; 33.3% (n = 6/18) in 1st-AMB+POSnew versus 52.0% (n = 26/50) in 1st-AMB; and 0.0% (n = 0/22) in SAL-POSnew versus 4.4% (n = 2/45) in SAL-POSsusp]. Conclusions Posaconazole new formulations were effective in terms of treatment response and associated mortality of IM. While posaconazole new formulations may be an alternative for treatment of IM, the limited sample size of our study calls for a cautious interpretation of these observations.

Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection

AIDS ◽  
2000 ◽  
Vol 14 (7) ◽  
pp. 845-852 ◽  
Author(s):  
Carl J. Fichtenbaum ◽  
Robert Zackin ◽  
Natasa Rajicic ◽  
William G. Powderly ◽  
L. Joseph Wheat ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Amphotericin B ◽  
Oral Candidiasis ◽  
Oral Suspension

Aging and Autism

2012 ◽  
Vol 17 (2) ◽  
pp. 69-75 ◽  
Author(s):  
Pamela A. Smith
Keyword(s):  
Health Care ◽  
Autism Spectrum Disorders ◽  
Patient Group ◽  
Older Patients ◽  
Geriatric Patients ◽  
Recent Literature ◽  
Communication Disorders ◽  
Autism Spectrum ◽  
Need For Support ◽  
Spectrum Disorders

In this article, I will review the available recent literature about the aging population with autism, a patient group that researchers know little about and a group that is experiencing a growing need for support from communication disorders professionals. Speech-language pathologists working with geriatric patients should become familiar with this issue, as the numbers of older patients with autism spectrum disorders is likely to increase. Our profession and our health care system must prepare to meet the challenge these patients and residents will present as they age.

Sign in / Sign up

Export Citation Format

Share Document